Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 22 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-5.36 Insider Own72.00% Shs Outstand23.20M Perf Week-2.11%
Market Cap389.05M Forward P/E- EPS next Y-1.63 Insider Trans-0.16% Shs Float12.36M Perf Month1.15%
Income-130.43M PEG- EPS next Q-0.36 Inst Own33.23% Short Float1.30% Perf Quarter-40.67%
Sales0.00M P/S- EPS this Y98.98% Inst Trans1.29% Short Ratio1.35 Perf Half Y16.69%
Book/sh5.50 P/B1.60 EPS next Y-9.09% ROA-61.33% Short Interest0.16M Perf Year-17.43%
Cash/sh6.00 P/C1.47 EPS next 5Y- ROE-68.39% 52W Range6.69 - 47.17 Perf YTD-4.55%
Dividend Est.- P/FCF- EPS past 5Y- ROI-48.81% 52W High-81.32% Beta-0.64
Dividend TTM- Quick Ratio42.80 Sales past 5Y0.00% Gross Margin- 52W Low31.69% ATR (14)0.98
Dividend Ex-DateAug 03, 2015 Current Ratio42.80 EPS Y/Y TTM-103111.54% Oper. Margin0.00% RSI (14)42.11 Volatility8.58% 11.78%
Employees33 Debt/Eq0.10 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price32.50
Option/ShortNo / Yes LT Debt/Eq0.10 EPS Q/Q-12154.84% Payout- Rel Volume1.62 Prev Close8.99
Sales Surprise- EPS Surprise-45.82% Sales Q/Q- EarningsJun 14 BMO Avg Volume118.59K Price8.81
SMA20-0.97% SMA50-13.86% SMA200-24.23% Trades Volume189,228 Change-2.00%
Date Action Analyst Rating Change Price Target Change
Apr-22-24Initiated Wells Fargo Overweight $30
Apr-15-24Initiated Guggenheim Buy $34
Mar-28-24Initiated UBS Buy $37
Mar-08-24Initiated Morgan Stanley Overweight $40
Feb-20-24Initiated Leerink Partners Outperform $31
Jul-18-24 08:00AM
Jun-14-24 07:01AM
May-29-24 07:30AM
May-15-24 04:05PM
May-02-24 04:05PM
08:56AM Loading…
Apr-09-24 08:56AM
Mar-11-24 05:16PM
Mar-05-24 07:00AM
Feb-14-24 06:50AM
Jan-30-24 07:00AM
Jan-29-24 07:00AM
Dec-22-23 05:00PM
Dec-19-23 07:00AM
07:00AM Loading…
Nov-29-23 07:00AM
Nov-13-23 09:55AM
Nov-02-23 07:00AM
Nov-01-23 07:30AM
enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Glickman Richard MDirectorMay 28 '24Option Exercise0.8912010724,675May 29 06:12 PM
FONDS DE SOLIDARITE DES TRAVAI10% OwnerApr 22 '24Sale15.0047,854717,8103,036,153Apr 22 05:22 PM
FONDS DE SOLIDARITE DES TRAVAI10% OwnerApr 19 '24Sale15.001001,5003,084,007Apr 22 05:22 PM
FONDS DE SOLIDARITE DES TRAVAI10% OwnerApr 18 '24Sale15.014,57568,6713,084,107Apr 22 05:22 PM
CHEUNG ANTHONY TZEYEWChief Technology OfficerMar 18 '24Option Exercise0.8952,94047,117102,873Mar 20 04:42 PM